M. Ian Phillips, PhD, DSc, FAHANorris Professor of Applied Life Sciences, Director of the Center for Rare Disease Therapies, Faculty Director for the PreMed Program
Cardiac Stem Cells, Heart Failure, Hemorrhagic Stroke, AAV Vectors, Gene Modification, Orphan Drugs, Stem Cell Therapy, Gene Therapy
Dr. Phillips received his PhD and DSc in pharmacology at the University of Birmingham in the United Kingdom. He was a postdoctoral fellow at the University of Michigan and an instructor and fellow in the Division of Biology at California Institute of Technology. From 1970-1980, he was Professor of Physiology at the University of Iowa. In 1977, as a Humboldt Foundation Scholar, Dr. Phillips spent a year at the University of Heidelberg in Germany and at the University of Zurich in Switzerland. He discovered the brain renin angiotensin system, a finding important to hypertension and stroke. In 1990, he served as Program Director of Neurobiology at the National Science Foundation in Washington, DC where he worked with the White House Office of Technology on "The Decade of the Brain". In 1999 he was at NIH From 1980-2002, Dr. Phillips was Chairman of Physiology at the University of Florida. At UF he built a modern gene-oriented Department of Physiology and founded the Division of Functional Genomics. In 2002, Dr. Phillips was appointed Vice President for Research at the University of South Florida, Tampa. As Vice President he worked to increase the economic impact of high tech in the SW of Florida and increase and construct a new research building and business incubator in the USF Research Park.
In 2006, Dr. Phillips joined Keck Graduate Institute of Applied Life Sciences (KGI) with his research lab and grants. He was appointed Norris Professor of Applied Life Sciences and founding director of the Center for Rare Disease Therapies. He also established the Post Baccalaureate Premedical Certificate Program. Among his honors, Dr. Phillips was awarded the 2002 Christopher Columbus Award for Science and Technology, the 1989 Lucian Award (McGill University) for research in circulatory disease, and a MERIT award from NIH (10 years of funding). He is an elected Fellow of the American Heart Association (FAHA) and Fellow of the American Association for the Advancement of Science (AAAS) and a member of the National Academy of Inventors. During his career, Dr. Phillips has published 12 books and more than 320 papers and reviews. The impact of his work is high (his h-index is 67 a measure of his consistently high impact publications). He has taught over 3,000 medical students and trained over 40 PhD students and postdoctoral fellows. He teaches writing an orphan drug designation, stem cells, gene therapy and rare diseases.
This course examines the role of genes, proteins and RNA in causing or combating diseases, and emphasizes the current conceptual and analytical tools that are brought to bear, and their limitations, on our understanding.
This course incorporates psychology with traditional premed professional development to offer students the most well-rounded preparation for medical school.
The scientific, engineering, and practical industrial aspects will be presented in a series of lectures.
This course will equip students with an understanding on how to write an orphan drug designation application.
The course will consist of tutoring, lectures, small group writing, editing, and reviewing by the faculty advisor, and between the student team participants. The course requires dedicated focus to the chosen topic and a series of deadlines that must be met.
Functions of angiotensin in the central nervous system
IM Phillips, Annual Review of Physiology 49 (1), 413-433, 1987 (cited by 710)
Paracrine action enhances the effects of autologous mesenchymal stem cell transplantation on vascular regeneration in rat model of myocardial infarction
YL Tang, Q Zhao, X Qin, L Shen, L Cheng, J Ge, MI Phillips
The Annals of thoracic surgery 80 (1), 229-237, 2005 (cited by 363)
Autologous mesenchymal stem cell transplantation induce VEGF and neovascularization in ischemic myocardium, YL Tang, Q Zhao, YC Zhang, L Cheng, M Liu, J Shi, YZ Yang, C Pan, J Ge, Regulatory peptides 117 (1), 3-10, 2004 (cited by 359)
Levels of angiotensin and molecular biology of the tissue renin angiotensin systems, M Ian Phillips, EA Speakman, B Kimura, Regulatory peptides 43 (1), 1-20, 1993 (cited by 329)
Upregulation of endothelial receptor for oxidized low-density lipoprotein (LOX-1) in cultured human coronary artery endothelial cells by angiotensin II type 1 receptor activation, DY Li, YC Zhang, MI Philips, T Sawamura, JL Mehta
Circulation research 84 (9), 1043-1049, 1999 (cited by 320)
Improved graft mesenchymal stem cell survival in ischemic heart with a hypoxia-regulated heme oxygenase-1 vector, YL Tang, Y Tang, YC Zhang, K Qian, L Shen, MI Phillips, Journal of the American College of Cardiology 46 (7), 1339-1350, 2005 (cited by 278)
Angiotensin II as a pro-inflammatory mediator.
MI Phillips, S Kagiyama, Current opinion in investigational drugs (London, England: 2000) 3 (4), 569-577, 2002 (cited by 204)
Hypoxic preconditioning enhances the benefit of cardiac progenitor cell therapy for treatment of myocardial infarction by inducing CXCR4 expression
YL Tang, W Zhu, M Cheng, L Chen, J Zhang, T Sun, R Kishore, MI Phillips, Circulation research 104 (10), 1209-1216, 2009 (cited by 180)
The multiple actions of angiotensin II in atherosclerosis
KM Schmidt-Ott, S Kagiyama, MI Phillips, Regulatory peptides 93 (1), 65-77, 2000 (cited by 166)
Brain renin angiotensin in disease
MI Phillips, EM De Oliveira, Journal of molecular medicine 86 (6), 715-722, 2008 (cited by 106)
Dr. Phillips discovered an independent hormonal system, the tissue renin angiotensin system, in the brain, heart, blood vessels and fat cells. His discoveries have broad significance for the development of new antihypertensive drugs. He was previously a consultant for Merck, Squibb and Hoechst. At the University of Florida, he initiated a gene therapy and stem cell therapy approach to hypertension and heart diseases. At KGI, he is pursuing his stem cell therapy studies full time.
Key Research Capabilities
Capabilities of the Phillips lab include cell culture, stem cell culture, stem cell isolation and differentiation, micro-RNA identification and expression regulation, antisense inhibition, gene engineering, gene modification, quantitative real time PCR, immunohistochemistry, fluorescence and confocal microscopy, and standard molecular biology techniques and can accommodate collaborations on exercise and heart size, stroke and hemorrhage.
Gene Vector Control of Bleeding: In many situations such as combat injury, surgery, rare bleeding diseases and cerebral stoke, hemorrhage needs to be stopped to prevent death. The Phillips lab has developed an automatic gene vector hemostat based on genetic engineering and testing in human endothelial cells. The vector responds to the oxgyen change in injured tissues, and releases clotting factors locally in small enough amounts to stop bleeding but not cause thrombosis. The Phillips lab collaborates with the US Army Surgical Institute in San Antonio, Texas and the University of South Florida, Tampa for study of battlefield combat injuries and with the neurology department of University of California, San Diego for stroke studies.
Orphan Drug Products: Dr. Phillips directs the Center for Rare Disease Therapies, which has many research activities including the search for drugs that can be developed to treat rare diseases. The Center runs workshops with the FDA, projects sponsored by drug companies, and patient advocate groups specializing in rare diseases.
Future Research Interests
Future research interests of the Phillips lab include microRNA gene expression regulation of ventricular hypertrophy and the Renin-Angiotensin system, automatic cessation of hemorrhage in complex surgery, rare diseases and rare disease health policy.
|M. Ian Phillips, PhD, DSc, FAHA|
|Location:||Building 535, Room 156B|